214 related articles for article (PubMed ID: 32730744)
1. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
[TBL] [Abstract][Full Text] [Related]
5. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
Maus MV; Haas AR; Beatty GL; Albelda SM; Levine BL; Liu X; Zhao Y; Kalos M; June CH
Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
[TBL] [Abstract][Full Text] [Related]
6. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
Kokalaki E; Ma B; Ferrari M; Grothier T; Hazelton W; Manzoor S; Costu E; Taylor J; Bulek A; Srivastava S; Gannon I; Jha R; Gealy R; Stanczuk L; Rizou T; Robson M; El-Kholy M; Baldan V; Righi M; Sillibourne J; Thomas S; Onuoha S; Cordoba S; Pule M
Mol Ther; 2023 Jul; 31(7):2089-2104. PubMed ID: 36945773
[TBL] [Abstract][Full Text] [Related]
8. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
[TBL] [Abstract][Full Text] [Related]
9. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract][Full Text] [Related]
10. A New Frontier: CD19 Chimeric Antigen Receptor T-Cell Therapy.
Alcocer Alkureishi L; Hageman JR
Pediatr Ann; 2024 May; 53(5):e157-e158. PubMed ID: 38700917
[No Abstract] [Full Text] [Related]
11. Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer.
Hung HC; Fan MH; Wang D; Miao CH; Su P; Liu CL
BMC Med; 2023 Sep; 21(1):338. PubMed ID: 37667257
[TBL] [Abstract][Full Text] [Related]
12. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
Liu X; Onda M; Watson N; Hassan R; Ho M; Bera TK; Wei J; Chakraborty A; Beers R; Zhou Q; Shajahan A; Azadi P; Zhan J; Xia D; Pastan I
Proc Natl Acad Sci U S A; 2022 May; 119(19):e2202439119. PubMed ID: 35512094
[TBL] [Abstract][Full Text] [Related]
13. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion.
Uslu U; Sun L; Castelli S; Finck AV; Assenmacher CA; Young RM; Chen ZJ; June CH
Nat Commun; 2024 May; 15(1):3933. PubMed ID: 38730243
[TBL] [Abstract][Full Text] [Related]
14. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells.
Jiang H; Song B; Wang P; Shi B; Li Q; Fan M; Di S; Yang J; Li Z
Protein Cell; 2017 Dec; 8(12):926-931. PubMed ID: 28929447
[No Abstract] [Full Text] [Related]
15. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.
Quach HT; Skovgard MS; Villena-Vargas J; Bellis RY; Chintala NK; Amador-Molina A; Bai Y; Banerjee S; Saini J; Xiong Y; Vista WR; Byun AJ; De Biasi A; Zeltsman M; Mayor M; Morello A; Mittal V; Gomez DR; Rimner A; Jones DR; Adusumilli PS
Cancer Immunol Res; 2023 Oct; 11(10):1314-1331. PubMed ID: 37540803
[TBL] [Abstract][Full Text] [Related]
16. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Lesch S; Blumenberg V; Stoiber S; Gottschlich A; Ogonek J; Cadilha BL; Dantes Z; Rataj F; Dorman K; Lutz J; Karches CH; Heise C; Kurzay M; Larimer BM; Grassmann S; Rapp M; Nottebrock A; Kruger S; Tokarew N; Metzger P; Hoerth C; Benmebarek MR; Dhoqina D; Grünmeier R; Seifert M; Oener A; Umut Ö; Joaquina S; Vimeux L; Tran T; Hank T; Baba T; Huynh D; Megens RTA; Janssen KP; Jastroch M; Lamp D; Ruehland S; Di Pilato M; Pruessmann JN; Thomas M; Marr C; Ormanns S; Reischer A; Hristov M; Tartour E; Donnadieu E; Rothenfusser S; Duewell P; König LM; Schnurr M; Subklewe M; Liss AS; Halama N; Reichert M; Mempel TR; Endres S; Kobold S
Nat Biomed Eng; 2021 Nov; 5(11):1246-1260. PubMed ID: 34083764
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
Tsujikawa T; Crocenzi T; Durham JN; Sugar EA; Wu AA; Onners B; Nauroth JM; Anders RA; Fertig EJ; Laheru DA; Reiss K; Vonderheide RH; Ko AH; Tempero MA; Fisher GA; Considine M; Danilova L; Brockstedt DG; Coussens LM; Jaffee EM; Le DT
Clin Cancer Res; 2020 Jul; 26(14):3578-3588. PubMed ID: 32273276
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.
Showalter SL; Huang YH; Witkiewicz A; Costantino CL; Yeo CJ; Green JJ; Langer R; Anderson DG; Sawicki JA; Brody JR
Cancer Biol Ther; 2008 Oct; 7(10):1584-90. PubMed ID: 19039293
[TBL] [Abstract][Full Text] [Related]
19. Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083755
[TBL] [Abstract][Full Text] [Related]
20. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.
Asnani M; Hayer KE; Naqvi AS; Zheng S; Yang SY; Oldridge D; Ibrahim F; Maragkakis M; Gazzara MR; Black KL; Bagashev A; Taylor D; Mourelatos Z; Grupp SA; Barrett D; Maris JM; Sotillo E; Barash Y; Thomas-Tikhonenko A
Leukemia; 2020 Apr; 34(4):1202-1207. PubMed ID: 31591467
[No Abstract] [Full Text] [Related]
[Next] [New Search]
